This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Health Winners & Losers

Genentech's (DNA) shares fell Wednesday after the company's sales of its highly touted cancer drug Avastin came in short of expectations for the second quarter. Even though overall earnings and revenue were strong, and Genentech lifted its full-year forecast, shares fell 3.6% to $81.05.

Medical-device maker Cyberonics (CYBX) sank following an announcement that the company would delay filing its form 10-K with the Securities and Exchange Commission pending the completion of an inquiry into its previous stock-option grants and accounting issues arising from the results of the review.

Separately, Cyberonics said it received Food and Drug Administration approval of a new label for its vagus nerve-stimulating device used to treat epilepsy and depression, as well as new programming software for the VNS therapy device model 250. Shares were down 0.9% to $21.62.

Shares of Teva Pharmaceutical (TEVA - Get Report) fell after the company said it was ending its marketing agreement with Japanese pharmaceuticals company Eisai for the Parkinson's disease drug Azilect. The companies entered the agreement in May 2003, and since then, Teva's neuroscience sales efforts have doubled, the company says. Shares fell 1.6% to $31.57.

Sanofi-Aventis (SNY - Get Report) dipped despite results from a recent study showing its drug Ambien CR is well tolerated and effective in improving sleep for up to six months in patients with chronic primary insomnia. Shares fell 30 cents to $49.38 lately.

Genzyme's (GENZ) stock rose 8% to $62.61 after the maker of drugs for rare diseases reported earnings and revenue that beat estimates.

The company reported second-quarter revenue of $793.4 million, beating estimates of $778.6 million. Excluding certain charges, the company earned 68 cents a share in the second quarter vs. analysts' estimates of 66 cents a share.

Shares of Hi-Tech Pharmacal (HITK), a manufacturer of liquid prescription and over-the-counter drugs and nutritional products, rose 6.2% to $18.26 after the company reported fourth-quarter results that included sales growth of 15% and a 33% increase in earnings per share.

Kos Pharmaceuticals' (KOSP) shares gained 18 cents to $39.16 after the company said it applied for FDA approval of a complete dosage range for its once-daily cholesterol drug Niaspan.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
SNY $38.28 -0.55%
TEVA $54.05 -5.00%
AAPL $93.91 -0.38%
FB $101.45 0.45%
GOOG $680.50 -0.53%


Chart of I:DJI
DOW 15,630.08 -284.66 -1.79%
S&P 500 1,830.44 -21.42 -1.16%
NASDAQ 4,262.3280 -21.2640 -0.50%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs